2'-Fucosyllactose 41263-94-9

99% up by HPLC

Product categories

New Products

Product Details

Product Information

Product name	2'-Fucosyllactose
CAS No.	41263-94-9
Molecular Formula	C18H32O15
Molecular Weight	488.443
Molecular Structure
Quality Standard	99% up by HPLC
Appearance	White to off-white powder

COA

Items	Standard	Results
Appearance	White to ivory-coloured spray-dried powder	Complies
Solubilityl in water	min.500g/L(ambient temperature)	Complies
Appearance in solution	colourless to slightly yellow	Complies
GMO detection	negative	negative
2'-Fucosyllactose	≥90%(%DM)	90.8%
Lactose	≤5% (Area)	0.8%
Fucose	≤3% (Area)	0.6%
3-Fucosyllactose	≤5% (Area)	1.8%
Difucosyllactose	≤5% (Area)	2.0%
Fucosyl-Galactose	≤3% (Area)	1.0%
Water Content	≤9.0%	6.2%
Protein content	≤100μg/g	0.2μg/g
Total Ash	≤0.5%	0.12%
Conclusion	Qualified

Usage

2'-Fucosyllactose (2'-FL) is a type of human milk oligosaccharide (HMO) that is naturally found in breast milk. It is a complex carbohydrate that cannot be digested by infants, but it plays an important role in promoting the growth and development of beneficial gut bacteria, as well as supporting the immune system.

The benefits of 2'-FL include:

1. Prebiotic effects: 2'-FL promotes the growth of beneficial gut bacteria, such as Bifidobacterium and Lactobacillus, while inhibiting the growth of harmful bacteria. This helps to support a healthy digestive system and immune function.

2. Anti-inflammatory effects: 2'-FL has been shown to have anti-inflammatory properties, which may help to reduce inflammation and support overall health.

3. Immune system support: 2'-FL supports the development and function of the immune system, including the production of antibodies and the activation of immune cells.

4. Cognitive development: Studies have shown that infants who consume breast milk containing 2'-FL have better cognitive development and may have a lower risk of developmental delays.

5. Reduced risk of infections: Infants who consume breast milk containing 2'-FL have a lower risk of infections, including respiratory infections and diarrhea.

Overall, 2'-FL is a beneficial component of breast milk that supports the growth and development of infants and provides important health benefits. It is now being added to infant formula and other products as a way to provide similar benefits to infants who are not able to consume breast milk.

Hot Tags : 41263-94-9 2'-Fucosyllactose Fucosyllactose Human Milk Oligosaccharides 2\'-FL HMO

Send A Message

Related Products

Dapagliflozin intermediate/ D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-, tetraacetate, (1S)-/ 461432-25-7

99% up by HPLC, total impurity < 0.1%

Nicotinamide Riboside Chloride/ NRcl 23111-00-4

98% up by HPLC

Ethyl 6-chloro-4-hydroxy[1,5]naphthyridine-3-carboxylate 127094-58-0

98% up by HPLC

Tulathromycin 217500-96-4

97% up, Vet-GMP / DMF

Inositol Vitamin B8 87-89-8

99% up by HPLC, Food grade, GMP, HACCP, HALAL, Kosher, FAMI-QS

Fusidic acid 6990-06-3

Product Information Product name Fusidic acid; Fusidine CAS No. 6990-06-3 Molecular Formula C31H48O6 Molecular Weight 516.719 Quality Standard 97.5% up by HPLC Appearance White or almost white, crystalline powder COA ANALYSIS SPECIFICATION RESULTS Appearance White or almost white, crystalline powder White crystalline powder Solubility Practically insoluble in water, freely soluble in ethanol (96%) Practically insoluble in water, freely soluble in ethanol (96%) Identification IR: IR absorption spectrum of sample is in identical with that of reference substance IR absorption spectrum of sample is in identical with that of reference substance Reaction of sodium: The residue does not give reaction (a) of sodium The residue does not give reaction (a) of sodium Water 1.4%-2.0% 1.7% Sulfated ash ≤0.2% 0.1% Assay (on anhydrous basis) 97.5% - 101.0% 99.9% Particle size 90% Particle diamite < 20 μm 100% Particle diamite < 20 μm Related substance Impurity M ≤ 1.0% 0.1% Impurity G ≤ 0.7% Not detected Impurity L ≤ 0.5% Not detected Impurity B ≤ 0.4% Not detected Impurity A ≤ 0.3% Not detected Impurity H ≤ 0.10% Not detected Impurity C ≤ 0.2% Not detected Impurity D ≤ 0.2% Not detected Impurity F ≤ 0.2% Not detected Impurity I ≤ 0.2% Not detected Impurity K ≤ 0.2% Not detected Impurity K ≤ 0.2% Not detected Max unknown impurity ≤ 0.10% Not detected Total impurities ≤ 2.0% 0.1% Residual solvents Ethanol ≤ 5000pm Not detected Methanol ≤ 3000pm Not detected Ethyl acetate ≤ 5000pm Not detected N-hexane ≤ 290pm Not detected Microbial limit Bacteria ≤ 100cfu/g Not detected Total molds and yeasts ≤ 10cfu/g Not detected Staphylococcus aureus: None Not detected Pseudomonas aeruginosa: None Not detected Conclusion The sample complies with EP. Usage The application of Fusidic acid: Fusidic acid is primarily used as an antibiotic to treat bacterial infections. It is commonly applied topically, as a Fusidic acid cream or Fusidic acid ointment, to treat skin infections such as impetigo, infected cuts or wounds, and infected eczema. In some cases, it may also be prescribed orally or intravenously to treat systemic infections, particularly those caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA). Additionally, fusidic acid has been used in combination with other medications for the treatment of various infections. For example, it may be combined with corticosteroids to treat inflammatory skin conditions or with hydrocortisone to treat otitis externa (outer ear infections). Fusidic acid works by inhibiting bacterial protein synthesis, specifically targeting the ribosomes within bacterial cells. This mechanism of action makes it effective against a wide range of bacteria, particularly Staphylococcus species. However, it is important to use fusidic acid judiciously to prevent the development of antibiotic resistance. *Products under the patent are only for R&D use